Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of LY3209590 vs Insulin Glargine on Hypoglycemia in T2DM
NCT04957914Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Insulin efsitora alfa in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Primary endpoint: Incidence of Documented Hypoglycemia at Day 186. Started Jul 2021; status: completed.
02
Drugs
Insulin efsitora alfa
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04957914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04957914.